Abstract: Patients with malignant tumors have a high incidence of venous thromboembolism (VTE). In addition, VTE is an important factor in the progression of cancer and the death of patients with cancer. Deep vein thrombosis (DVT), which comprises proximal deep vein thrombosis (PDVT) and isolated distal deep vein thrombosis (IDDVT), of the lower extremities accounts for a large proportion of VTEs and causes great harm. The risk of and management strategies for PDVT have been well studied. However, we know little about IDDVT, which accounts for about half the cases of DVT of the lower extremities. The clinical risk of and therapies for cancer-related IDDVT are still being studied. We summarize the current status of clinical studies on the management of patients with IDDVT, especially those with a history of cancer.